# 

## Gram-Negative Bacteremia: Frequency of an IOTA (Intravenous to Oral Transition of Antimicrobial Therapy) Victoria Wilson, PharmD Candidate Sara Gardner, PharmD Candidate Beth Cady, PharmD, BCPS

Backg	Jround		
<ul> <li>Each year, nearly 250,000 patients in the Unit particular type of bloodstream infection called bacteremia."<sup>1</sup></li> </ul>			
This infection develops when infection, overcome host bar response, and spread to the bacteremia has a high morta	riers including the bloodstream. Gra		
<ul> <li>populations.<sup>2</sup></li> <li>Several studies suggest that conversion to oral an negative bacteremia has similar outcomes to strict particularly from a urinary source of infection.<sup>3</sup></li> <li>In these studies, the prominent pathogens of urinary infection and subsequent bacteremia <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i></li> <li>Due to lack of definitive guidance, clinicians may be advocate for an early transition from IV to oral antipatients with gram-negative bacteremia.</li> <li>Benefits of transitioning patients from IV to oral antipatients definitive guidance antibiotics may hospital stay and improve patients' quality or <b>Purpose</b></li> </ul>			
Determine the frequency at which these patients a oral antibiotic therapy for this type of infe			
Methods			
All <i>E. coli</i> and <i>Klebsiella</i> pneumoniae bacteremia from 01/01/2019 – 5/31/2022	Exclue Polymicrob Sources oth		
Analysis: <b>100 encounters</b>	Inability to t Lack of suscept		

e00234-20. doi: 9824. 3. Sutton JD, Stevens VW, Chang NN, Khader K, Timbrook TT, Spivak ES. Oral  $\beta$ -Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. JAMA Netw Open. 2020;3(10):e2020166. doi:10.1001/jamanetworkopen.2020.20166

### States develop a gram-negative

- ze an initial site of e immune am-negative arly in vulnerable
- ntibiotics for gramtly IV regimens,
- causing the a were
- be hesitant to tibiotic therapy in
- oral therapy are reduce length of of life.

are transitioned to ection.

## uded (72):

bial infections her than urinary take oral meds tibility to oral meds

### Hasan Gram-negative 8-503 genesis of Gram-

## Inclusion criteria for chart evaluation:


- Age  $\geq$  18 years old
- Monomicrobial infections
- Urinary sources
- Susceptibility to oral medications
- IV therapy for 24 hours
- Negative repeat blood cultures, if collected
- Clinical improvement defined by downtrending white blood cell count, afebrile for 48 hours, blood pressure/heart rate/respiratory rate within normal limits

## Patients Eligible for IV-Oral Stepdown Therapy


No 72.0%

	Eligible
Pathogen	and
	Switche
E. coli	2
<i>K.</i>	
Pneumoniae	

## Southern Illinois University Edwardsville School of Pharmacy



# **Results (cont.)** Eligible Patients Switched from IV to PO Therapy



## **Reasons for not switching**

ontraindication to FQ	Concomitant infection	Unknown	
3		2	
Conclusion			

71% of patients who met the inclusion criteria were switched from IV to oral antibiotics in the presence of monomicrobial *E. coli* from a urinary source with clinical improvement.

Zero patients with *Klebsiella pneumoniae* were eligible to switch.

According to our results, there appears to be an opportunity to transition more patients from IV to oral with a gram-negative

Future research opportunities: more patients, evaluation of which oral medication was used, whether the patient received an ID consult, and implementation for an alert to switch in Theradoc.

## Disclosures

Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation

Further questions: J & Sa ardn@siue.edu.